Loading stock data…
BOLD
$1.57+0.11 (+7.53%)
Market ClosedLast close May 1
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Boundless Bio, Inc. in the Healthcare sector is trading at $1.57. The stock is currently 9% below its 52-week high of $1.73, remaining 28.7% above its 200-day moving average. Technical signals show overbought RSI of 73 and bearish MACD signal, explaining why BOLD maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.57
Potential Upside
5%
Whystock Fair Value$1.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$34.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.99%
Volume
Today's trading volume
69,937
Recent News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).